FIG. 1.

Development of JUNV Candid1 live attenuated vaccine. (A) Vaccine history. The original vaccine virus was developed by successive passages in guinea pigs (GP) and mouse brains (MB), followed by a clonal selection in FRhl cells (5, 32). (B) Genetic characterization of the recombinant vaccine. The recombinant vaccine virus was developed by reverse genetics as described before (3). Minor changes in the sequences of S and L RNA segments were maintained as selective markers to differentiate the recombinant from the wild-type vaccine viruses.